DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26317460.
- Also identified by DOI 10.1016/j.cell.2015.08.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
DNA demethylating agents are approved for some blood malignancies and are under active investigation in solid tumors, but how these drugs work has remained unclear. In this issue of Cell, two groups show that these agents activate a toxic cellular antiviral program through transcriptional activation of endogenous retroviral sequences.
Medical subject headings
- Antimetabolites, Antineoplastic
- Azacitidine
- Colorectal Neoplasms
- DNA Methylation
- Interferon Type I
- Melanoma